NCT03393481View on ClinicalTrials.gov

Prevention of Thromboembolic Events in Total Knee Replacement Patients

PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

October 3, 2018

Primary Completion Date

January 8, 2020

Study Completion Date

April 17, 2020

Conditions
Thrombotic Disorders
Interventions
DRUG

MAA868

MAA868 dose 1 and dose 2, single administration, subcutaneous,

DRUG

Enoxaparin

Enoxaparin 40 mg, o.d X 10 days

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY